EI

267.3

-0.22%↓

SHL.DE

49.84

-0.84%↓

ARGX

532.2

-2.13%↓

FRE

39.41

-0.53%↓

PHIA

22.9

-2.84%↓

EI

267.3

-0.22%↓

SHL.DE

49.84

-0.84%↓

ARGX

532.2

-2.13%↓

FRE

39.41

-0.53%↓

PHIA

22.9

-2.84%↓

EI

267.3

-0.22%↓

SHL.DE

49.84

-0.84%↓

ARGX

532.2

-2.13%↓

FRE

39.41

-0.53%↓

PHIA

22.9

-2.84%↓

EI

267.3

-0.22%↓

SHL.DE

49.84

-0.84%↓

ARGX

532.2

-2.13%↓

FRE

39.41

-0.53%↓

PHIA

22.9

-2.84%↓

EI

267.3

-0.22%↓

SHL.DE

49.84

-0.84%↓

ARGX

532.2

-2.13%↓

FRE

39.41

-0.53%↓

PHIA

22.9

-2.84%↓

Search

Sanofi SA

Abierto

SectorSanidad

100.08 -2.32

Resumen

Variación precio

24h

Actual

Mínimo

97.94

Máximo

102.28

Métricas clave

By Trading Economics

Ingresos

-2.3B

499M

Ventas

-6.5B

7.6B

P/B

Media del Sector

23.216

63.778

BPA

1.31

Rentabilidad por dividendo

3.79

Margen de beneficios

6.539

Empleados

82,878

EBITDA

-3.7B

563M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+13.01% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.79%

2.39%

Próximas Ganancias

24 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-6B

125B

Apertura anterior

102.4

Cierre anterior

100.08

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

96 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Sanofi SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 mar 2025, 06:43 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

5 feb 2025, 13:41 UTC

Ganancias

Santander Shares Get Boost From Buyback, Better-Than-Expected Results -- 2nd Update

5 feb 2025, 07:10 UTC

Ganancias

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations -- Update

5 feb 2025, 06:39 UTC

Ganancias

Santander Plans $10.4 Billion in Buybacks After Results Beat Expectations

26 mar 2025, 06:19 UTC

Charlas de Mercado
Ganancias

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 mar 2025, 10:08 UTC

Charlas de Mercado

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 mar 2025, 09:00 UTC

Principales Noticias

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 mar 2025, 06:05 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mar 2025, 06:05 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mar 2025, 06:04 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Pay $600M Upfront

20 mar 2025, 06:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mar 2025, 06:00 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 mar 2025, 09:33 UTC

Acciones populares

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 mar 2025, 23:00 UTC

Principales Noticias

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 mar 2025, 09:50 UTC

Ganancias

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 mar 2025, 09:49 UTC

Ganancias

Santander Increased 2024 Cash Payments by 19%

24 feb 2025, 08:56 UTC

Charlas de Mercado
Ganancias

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 feb 2025, 08:30 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

19 feb 2025, 06:35 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Transaction Remains Subject to Obtaining Customary Regulatory Approvals

19 feb 2025, 06:34 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Closing Is Expected to Take Place in 2Q at the Earliest

19 feb 2025, 06:34 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Terms of Transaction Remain Unchanged From Those Previously Disclosed

19 feb 2025, 06:33 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Remain Significant Shareholder in Opella Consumer Business

19 feb 2025, 06:33 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Bpifrance to Participate as Minority Shareholder With 2% Stake in Opella

19 feb 2025, 06:33 UTC

Adquisiciones, fusiones, absorciones

Sanofi: This Follows Completion of Required Social and Corporate Procedures

19 feb 2025, 06:32 UTC

Adquisiciones, fusiones, absorciones

Sanofi Signs Deal for Sale of 50% Controlling Stake in Opella to CD&R

19 feb 2025, 06:31 UTC

Adquisiciones, fusiones, absorciones

Sanofi, CD&R Sign Opella Share Purchase Agreement

14 feb 2025, 10:55 UTC

Charlas de Mercado
Ganancias
Adquisiciones, fusiones, absorciones

NatWest CEO Confident on Organic Growth Prospects -- Market Talk

5 feb 2025, 07:48 UTC

Charlas de Mercado
Ganancias

Santander's Results, Guidance, Return Plans All Look Strong -- Market Talk

5 feb 2025, 06:01 UTC

Ganancias

Santander: Franco Joins Getnet From Canadian Fintech Company Nuvei

5 feb 2025, 06:01 UTC

Ganancias

Santander: Getnet's Current CEO, Kush Saxena, Has Decided to Resign

Comparación entre iguales

Cambio de precio

Sanofi SA previsión

Precio Objetivo

By TipRanks

13.01% repunte

Estimación a 12 Meses

Media 115.177 EUR  13.01%

Máximo 125 EUR

Mínimo 92 EUR

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

9

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

101.1 / 103.88Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

96 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.